CONVERGE
Lung cancer
INTRATUMORAL STUDY.
A Phase 2 study of JNJ-90301900 (NBTXR3)/RT plus chemoradiation followed by durvalumab in locally advanced and unresectable stage 3 NSCLC
A Phase 2 study of JNJ-90301900 (NBTXR3)/RT plus chemoradiation followed by durvalumab in locally advanced and unresectable stage 3 NSCLC
Phase
Compound
JNJ-90301900 (NBTXR3) + cCRT + durvalumab
NCT identifier
NCT06667908
Enrollment
N=~130
For more information, including
contact details, please visit
the J&J Clinical Trial Finder
contact details, please visit
the J&J Clinical Trial Finder
Study overview & design
Key eligibility criteria*:
- Locally advanced, unresectable, stage 3A or 3B NSCLC
- Candidate for SOC treatment of NSCLC by cCRT, followed by consolidation durvalumab treatment
- ≥1 target lesion (primary lung lesion or involved lymph nodes) amenable to intratumoral and/or intranodal injection and IMRT
- ECOG PS 0 or 1
Study
design
Primary outcomes:
- Objective response rate
Secondary outcomes‡:
- PFS
- DOR
- Objective response rate, DCR post-cCRT, and pre-cIT
- Patterns of failure
- Safety
*Not a complete list of inclusion and exclusion criteria. †Followed by postinjection CT confirmation. ‡Not a complete list of secondary outcomes.
cCRT, concurrent chemoradiotherapy; cIT, cancer immunotherapy; CT, computed tomography; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; IMRT, intensity-modulated radiation therapy; NSCLC, non–small cell lung cancer; PFS, progression-free survival; R, randomized; RT, radiation therapy; SOC, standard of care.